Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study

Background. There is a need to prevent or minimize bone loss associated with antiretroviral treatment (ART) initiation. We compared maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)–containing ART. Methods. This was a double-blind, placebo-controlled trial. ART-naive subjects with human immuno...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Infect Dis
Päätekijät: Taiwo, Babafemi O., Chan, Ellen S., Fichtenbaum, Carl J., Ribaudo, Heather, Tsibris, Athe, Klingman, Karin L., Eron, Joseph J., Berzins, Baiba, Robertson, Kevin, Landay, Alan, Ofotokun, Igho, Brown, Todd
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2015
Aiheet:
HIV/AIDS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4560904/
https://ncbi.nlm.nih.gov/pubmed/26060295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ455
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia